mortality/aging
• none survive past 12 weeks of age
• treatment with sodium fumarate dibasic or Mdivi-1 (a specific Dnm1l inhibitor) to target mitochondria substantially prolongs the survival of the mice
|
cardiovascular system
• severe abnormalities in myofibril/sarcomere organization and intramitochondrial structure at 8 weeks of age
|
• at 8 weeks of age cristae malformations, electron-dense inclusions and hypodense compartments are seen
• at 8 weeks of age the number of mitochondria is increased and the size is decreased
• despite the increase in number of mitochondria the amount of mtDNA is reduced
• treatment with sodium fumarate dibasic or Mdivi-1 (a specific Dnm1l inhibitor) improves mitochondrial morphology
|
• in cardiomyocytes at 8 weeks of age
|
• thickening of the cardiac muscle by 3-4 weeks of age
|
• starting at 3 weeks of age
|
• develops at later stages
|
• present at 7 weeks but not at 4 weeks of age
|
• at later stages
• upregulation of pathological markers is seen primarily in the left ventricle
|
• deregulated cardiac contraction
• treatment with Mdivi-1 (a specific Dnm1l inhibitor) improves cardiac function
|
• decrease in left ventricular fractional shortening
|
growth/size/body
• starting at 3 weeks of age
|
• lower body weights in mice older than 6 weeks
• no difference in body weight is detected during the first 6 weeks of life
• ratio of tibialis anterior muscle weight to body weight is similar to controls
|
cellular
• at 8 weeks of age cristae malformations, electron-dense inclusions and hypodense compartments are seen
• at 8 weeks of age the number of mitochondria is increased and the size is decreased
• despite the increase in number of mitochondria the amount of mtDNA is reduced
• treatment with sodium fumarate dibasic or Mdivi-1 (a specific Dnm1l inhibitor) improves mitochondrial morphology
|
• in cardiomyocytes at 8 weeks of age
|
• mitochondrial dysfunction in the heart indicated by expression analysis, increase in protein oxidation, and decreases in TCA cycle related metabolites
• analysis of posttranslational modification of Dnm1l and other results suggest an increase in mitochondrial fission
|
• deregulated TCA cycle in cardiomyocytes
|
muscle
• severe abnormalities in myofibril/sarcomere organization and intramitochondrial structure at 8 weeks of age
|
• at 8 weeks of age cristae malformations, electron-dense inclusions and hypodense compartments are seen
• at 8 weeks of age the number of mitochondria is increased and the size is decreased
• despite the increase in number of mitochondria the amount of mtDNA is reduced
• treatment with sodium fumarate dibasic or Mdivi-1 (a specific Dnm1l inhibitor) improves mitochondrial morphology
|
• in cardiomyocytes at 8 weeks of age
|
• thickening of the cardiac muscle by 3-4 weeks of age
|
• at later stages
• upregulation of pathological markers is seen primarily in the left ventricle
|
• deregulated cardiac contraction
• treatment with Mdivi-1 (a specific Dnm1l inhibitor) improves cardiac function
|
• decrease in left ventricular fractional shortening
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
dilated cardiomyopathy | DOID:12930 |
OMIM:PS115200 |
J:345348 |